The FDA now requires earlier MRI screening for Alzheimer’s drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
The FDA now requires earlier MRI screening for Alzheimer’s drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
Copyright © Louis Velazquez. All Rights Reserved.